A RISK-BENEFIT APPRAISAL OF DRUGS USED IN THE MANAGEMENT OF PREMENSTRUAL-SYNDROME

被引:17
作者
MORTOLA, JF
机构
[1] Division of Reproductive Endocrinology and Infertility, Department of Obstetrics, Gynecology and Reproductive Biology, Beth Israel Hospital, Boston, Massachusetts
[2] Beth Israel Hospital, Boston, Massachusetts, 02215, 330 Brookline Avenue
关键词
D O I
10.2165/00002018-199410020-00005
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Recent advances in the understanding of the pathogenesis of premenstrual syndrome (PMS) have allowed the development of appropriate pharmacological interventions. Although at the present time there are no approved medications for this indication in the US, several well-designed studies have been conducted that guide the clinician's treatment of PMS. As a result, less-proven nonpharmacological modalities, such as dietary modification, exercise regimens and psychotherapy, are more quickly supplanted by the use of medication. Three classes of agents have been proven efficacious and are widely used to treat the disorder. These include benzodiazepines (especially alprazolam), selective serotonin reuptake inhibitors (especially fluoxetine), and gonadotropin-releasing hormone (GnRH) [luteinising hormone-releasing hormone (LHRH)] agonists. In addition to these medications which are used to treat the generalised syndrome of PMS, a variety of other drugs are used in the treatment of specific aspects of this disorder. Despite the success of these treatments, each has a substantial adverse effect profile which modulates their use in some patients. Knowledge of these potential adverse effects and their management should help optimise therapy. In addition, a variety of less well-proven pharmacological remedies are commonly in use. The adverse effects of these medications may well outweigh their benefits.
引用
收藏
页码:160 / 169
页数:10
相关论文
共 50 条
  • [1] Abraham G.E., Hargrove J.T., Effect of vitamin B6 on premenstrual symptomatology in women with premenstrual tension syndromes: a double blind crossover trial, Infertility, 3, pp. 155-165, (1980)
  • [2] Ashby C.R., Carr L.A., Cook C.L., Steptoe M.M., Franks D.D., Alteration of platelet serotonergic mechanisms and monoamine oxidase activity in premenstrual syndrome, Biological Psychiatry, 24, pp. 225-233, (1988)
  • [3] Ausel S., Schomberg D.W., Tyrey L., Hammond C.V., Vasomotor symptoms, serum estrogens and gonadotropin levels in surgical menopause, American Journal of Obstetrics and Gynecology, 126, pp. 165-169, (1976)
  • [4] Bancroft J., Boyle H., Warner P., Fraser H.M., The use of an LHRH antagonist, buserelin, in the long-term management of premenstrual syndromes, Clinical Endocrinology, 27, pp. 171-177, (1987)
  • [5] Barbieri R.L., Hornstein M.D., Medical therapy for endometriosis, Endometriosis, pp. 111-140, (1987)
  • [6] Braunwald E., Heart failure, Harrison’s principles of internal medicine, pp. 905-916, (1987)
  • [7] Budoff P.W., The use of prostaglandin inhibitors for the premenstrual syndrome, Journal of Reproductive Medicine, 28, pp. 469-478, (1983)
  • [8] The reduction in the risk of ovarian cancer associated with oral contraceptive use, New England Journal of Medicine, 316, pp. 650-657, (1987)
  • [9] Carlton G.J., Burnett J.W., Danazol and migraine, New England Journal of Medicine, 310, pp. 721-726, (1984)
  • [10] Casson P., Hahn P.M., Van Vugt D.A., Reid R.L., Lasting response to ovariectomy in severe intractable premenstrual syndrome, American Journal of Obstetrics and Gynecology, 162, pp. 99-103, (1990)